Author | Joseph E. Cruz, Pharm.D., BCPS


Cardiac Matters

March 15, 2017

Cangrealor is the first FDA-approved P2Y12 inhibitor.

PCSK9 Inhibitors: The First of Their Kind

January 26, 2017

The first of their kind, evolocumab and alirocumab belong to a new class of cholesterol lowering agents.

New combo therapy for chronic heart failure

December 15, 2016

Entresto® is a newly approved combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB) for patients who have chronic heart failure NYHA Class II-IV and reduced ejection fraction.